

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(₹ in Crores, except earning per share)

Sr. No	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2023 (Unaudited)	June 30, 2023 (Unaudited)	September 30, 2022 (Unaudited)	September 30, 2023 (Unaudited)	September 30, 2022 (Unaudited)	March 31, 2023 (Audited)
1	<b>Income</b>						
	Revenue from operations	78.36	51.44	100.94	129.80	162.02	278.09
	Other income	5.69	4.73	5.40	10.42	8.60	22.13
	<b>Total income</b>	<b>84.05</b>	<b>56.17</b>	<b>106.34</b>	<b>140.22</b>	<b>170.62</b>	<b>300.22</b>
2	<b>Expenses</b>						
	Cost of raw materials consumed	-	0.41	0.42	0.41	0.65	1.11
	Purchase of software products	0.85	2.06	4.06	2.91	4.73	7.83
	Change in inventory of security software products	1.22	(1.46)	(0.68)	(0.24)	0.02	0.39
	Employee benefits expenses	41.70	39.33	39.45	81.03	76.57	154.90
	Depreciation and amortisation expense	3.25	2.93	4.14	6.18	8.09	15.99
	Other expenses	23.62	26.18	29.31	49.80	50.62	111.98
	<b>Total expenses</b>	<b>70.64</b>	<b>69.45</b>	<b>76.70</b>	<b>140.09</b>	<b>140.68</b>	<b>292.20</b>
3	<b>Profit / (loss) before tax (1-2)</b>	<b>13.41</b>	<b>(13.28)</b>	<b>29.64</b>	<b>0.13</b>	<b>29.94</b>	<b>8.02</b>
4	<b>Tax expense</b>						
	Current tax						
	Pertaining to profit for the current year	0.31	-	7.28	0.31	7.40	1.28
	Adjustment in respect of current tax and deferred tax of previous years (Net)	-	-	-	-	-	(0.14)
	Deferred tax	0.20	(0.52)	0.20	(0.32)	0.20	0.48
	<b>Total tax expense</b>	<b>0.51</b>	<b>(0.52)</b>	<b>7.48</b>	<b>(0.01)</b>	<b>7.60</b>	<b>1.62</b>
5	<b>Profit / (loss) for the period (3-4)</b>	<b>12.90</b>	<b>(12.76)</b>	<b>22.16</b>	<b>0.14</b>	<b>22.34</b>	<b>6.40</b>
6	<b>Other comprehensive income / (loss) (net of tax)</b>						
	<b>Items that will not be reclassified subsequently to profit or loss:</b>						
	Re-measurement of defined benefit plans	0.26	0.13	0.33	0.39	(0.30)	0.13
	Net (loss) or gain on FVTOCI assets	(12.55)	-	(0.61)	(12.55)	(0.61)	(5.99)
	<b>Items that will be reclassified subsequently to profit or loss:</b>						
	Exchange differences on translation of foreign operations	0.02	(0.08)	(0.03)	(0.06)	(0.21)	(0.13)
	<b>Total other comprehensive income / (loss)</b>	<b>(12.27)</b>	<b>0.05</b>	<b>(0.31)</b>	<b>(12.22)</b>	<b>(1.12)</b>	<b>(5.99)</b>
7	<b>Total comprehensive income / (loss) (after tax) (5+6)</b>	<b>0.63</b>	<b>(12.71)</b>	<b>21.85</b>	<b>(12.08)</b>	<b>21.22</b>	<b>0.41</b>
8	Paid-up equity share capital (face value of ₹10 each)	53.08	53.07	58.07	53.08	58.07	53.07
9	Other equity	-	-	-	-	-	366.64
10	<b>Earnings per share of ₹10 each:</b> (not annualised for the quarter)						
	a) Basic	2.43	(2.40)	3.82	0.03	3.85	1.14
	b) Diluted	2.42	(2.40)	3.81	0.03	3.84	1.14

SA



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

Notes to financial results:

- 1 The above financial results for the quarter and half year ended September 30, 2023 have been subjected to limited review by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on October 26, 2023.
- 2 The Board of Directors of the Holding Company at its meeting held on July 21, 2022 and the shareholders by way of postal ballot on August 26, 2022, approved the buy back of the Holding Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Holding Company including promoters of the Holding Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹ 300 per share for an aggregate amount not exceeding ₹ 150. The Holding Company completed the Buy Back Process on October 28, 2022 and has complied with all the requisite formalities with SEBI and ROC.  
  
During the year ended March 31, 2023, as per the requirement of the Companies Act, 2013, an amount of ₹ 3.3 l and ₹ 176.63 (Including tax on buy back of ₹ 34.94) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹ 5.00 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹ 5.00. Further, transaction cost of buy back of shares of ₹ 1.85 has been reduced from retained earnings.
- 3 The following changes have taken place in Key Managerial Personnel of the Holding Company :  
Mr. Srinivasa Rao Anasingaraju resigned as Company Secretary w.e.f. July 17, 2023.  
Mr. Sarang Hari Deshpande appointed as Company Secretary w.e.f. October 26, 2023
- 4 Considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment has recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the entries carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at September 30, 2023.
- 5 The Group is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

For and on behalf of the Board of Directors



*Kailash Katkar*

Kailash Katkar  
Managing Director  
DIN No: 00397191

Place: Pune  
Date: October 26, 2023

**QUICK HEAL TECHNOLOGIES LIMITED**

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

**STATEMENT OF UNAUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023**

₹ in Crores

	As at September 30, 2023 (Unaudited)	As at March 31, 2023 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	92.68	97.56
(b) Intangible assets	1.92	2.77
(c) Intangible assets under development	0.15	0.15
(d) Investment Property	27.62	24.12
(e) Financial assets		
(i) Investments	8.35	21.49
(ii) Other financial assets	0.82	0.76
(f) Income tax assets (net)	29.04	22.33
(g) Other non-current assets	0.70	0.65
	<b>161.28</b>	<b>169.83</b>
<b>Current assets</b>		
(a) Inventories	4.33	4.50
(b) Financial assets		
(i) Investments	163.58	176.20
(ii) Trade receivables	107.50	122.65
(iii) Cash and cash equivalents	12.79	11.58
(iv) Bank balances other than (iii) above	0.28	0.27
(v) Other financial assets	1.91	1.49
(c) Other current assets	9.91	6.78
	<b>300.30</b>	<b>323.47</b>
<b>Total assets</b>	<b>461.58</b>	<b>493.30</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
(a) Equity share capital	53.08	53.07
(b) Share application money pending allotment	0.11	-
(c) Other equity	342.86	366.64
<b>Total equity</b>	<b>396.05</b>	<b>419.71</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Net employee defined benefit liabilities	-	0.60
(b) Other non-current liabilities	1.03	0.52
(c) Deferred tax liabilities (net)	0.35	0.53
	<b>1.38</b>	<b>1.65</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	2.51	1.94
(b) Total outstanding dues creditors other than micro enterprises and enterprises	38.04	46.67
(ii) Other financial liabilities	8.44	12.73
(b) Other current liabilities	14.20	10.03
(c) Net employee defined benefit liabilities	0.96	0.57
(d) Income tax liabilities (net)	-	-
	<b>64.15</b>	<b>71.94</b>
<b>Total liabilities</b>	<b>65.53</b>	<b>73.59</b>
<b>Total equity and liabilities</b>	<b>461.58</b>	<b>493.30</b>



**Quick Heal Technologies Limited**

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH11995PLC091408

**CONSOLIDATED STATEMENT OF UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2023**

₹ in Crores

	September 30, 2023	March 31, 2023
	Unaudited	Audited
<b>A. Cash flow from operating activities</b>		
Profit before tax	0.13	8.02
Adjustment to reconcile profit before tax to net cash flows:		
Liability write back	-	(1.88)
Net (gain) / loss foreign exchange differences	(0.14)	0.85
Employee share based payments expense	1.42	2.85
Depreciation and amortization expense	6.18	15.99
Interest income	0.04	(1.78)
Provision for doubtful debts and advances	4.64	5.15
Property, plant and equipment written off	0.03	-
(Profit) / Loss on sale of property, plant and equipment	(0.28)	(3.95)
Exchange difference on translation of foreign currency cash and cash equivalents	(0.01)	-
Income from Investment Property	(1.87)	(3.58)
Net gain on sale of investment	(0.78)	(3.20)
Net gain on FVTPL current investment	(5.21)	(6.88)
<b>Operating profit before working capital changes</b>	<b>4.15</b>	<b>11.59</b>
Movements in working capital:		
(Increase)/decrease in trade receivables	10.59	44.31
(Increase)/decrease in inventories	0.17	0.29
(Increase)/decrease in other financial assets	0.07	(0.88)
(Increase)/decrease in other assets	(3.18)	(3.38)
Increase/(decrease) in net employee defined benefit liabilities	0.31	0.07
Increase/(decrease) in trade payables	(8.06)	(1.08)
Increase/(decrease) in other financials liabilities	(3.06)	(2.83)
Increase/(decrease) in other current and non current liabilities	4.68	(9.28)
<b>Cash generated from operations</b>	<b>5.67</b>	<b>38.81</b>
Direct taxes paid (net of refunds)	(7.02)	(8.00)
<b>Net cash flow from operating activities (A)</b>	<b>(1.35)</b>	<b>30.81</b>
<b>B. Cash flow from investing activities</b>		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(5.71)	(4.08)
Proceeds from sale of property, plant and equipment	0.78	5.20
Purchase of investments	(146.84)	(400.60)
Sale of investments	166.04	524.53
Income from Investment Property	1.87	3.58
(Increase)/decrease in bank balances other than cash and cash equivalents	(0.01)	54.74
Interest received	(0.59)	1.86
<b>Net cash (used in) investing activities (B)</b>	<b>15.54</b>	<b>185.23</b>
<b>C. Cash flow from financing activities</b>		
Dividend paid on equity shares	(13.26)	(26.09)
Tax on Buyback	-	(34.94)
Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP by employees	0.27	0.72
Buyback Expenses	-	(1.85)
Payout on Buyback of equity shares	-	(150.00)
<b>Net cash flow (used in) financing activities (C)</b>	<b>(12.99)</b>	<b>(212.16)</b>
<b>Net (decrease) in cash and cash equivalents (A+B+C)</b>	<b>1.20</b>	<b>3.88</b>
Cash and cash equivalents at the beginning of the year	11.58	7.83
Effect of exchange differences on cash and cash equivalents held in foreign currency	0.01	(0.13)
<b>Cash and cash equivalents at the end of the year</b>	<b>12.79</b>	<b>11.58</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	-	0.02
Balances with banks		
On current account	11.07	9.47
On EEFC account	1.72	2.09
<b>Total cash and cash equivalents</b>	<b>12.79</b>	<b>11.58</b>



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023  
 (₹ in Crores, except earning per share)

Sr. No	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2023 (Unaudited)	June 30, 2023 (Unaudited)	September 30, 2022 (Unaudited)	September 30, 2023 (Unaudited)	September 30, 2022 (Unaudited)	March 31, 2023 (Audited)
1	<b>Income</b>						
	Revenue from operations	78.37	51.43	100.93	129.80	162.02	278.11
	Other income	5.68	4.73	5.38	10.41	8.57	22.38
	<b>Total income</b>	<b>84.05</b>	<b>56.16</b>	<b>106.31</b>	<b>140.21</b>	<b>170.59</b>	<b>300.49</b>
2	<b>Expenses</b>						
	Cost of raw materials consumed	-	0.41	0.42	0.41	0.65	1.11
	Purchase of security software products	0.84	2.06	4.06	2.90	4.73	7.83
	Change in inventory of security software products	1.22	(1.46)	(0.68)	(0.24)	0.02	0.39
	Employee benefits expenses	41.70	39.33	39.45	81.03	76.56	154.89
	Depreciation and amortisation expense	3.25	2.93	4.14	6.18	8.09	15.99
	Other expenses	23.63	26.29	29.34	49.92	50.56	111.09
	<b>Total expenses</b>	<b>70.64</b>	<b>69.56</b>	<b>76.73</b>	<b>140.20</b>	<b>140.61</b>	<b>291.30</b>
3	<b>Profit / (loss) before exceptional items and tax (1-2)</b>	<b>13.41</b>	<b>(13.40)</b>	<b>29.58</b>	<b>0.01</b>	<b>29.98</b>	<b>9.19</b>
4	Exceptional items (refer note 2)	-	-	-	-	-	(0.10)
5	<b>Profit / (loss) before tax (3-4)</b>	<b>13.41</b>	<b>(13.40)</b>	<b>29.58</b>	<b>0.01</b>	<b>29.98</b>	<b>9.29</b>
6	<b>Tax expense</b>						
	Current tax						
	Pertaining to profit for the current year	0.31	-	7.27	0.31	7.37	1.25
	Adjustments of current tax and deferred tax relating to earlier periods (Net)	-	-	-	-	-	(0.14)
	Deferred tax	0.20	(0.52)	0.20	(0.32)	0.20	0.48
	<b>Total tax expense</b>	<b>0.51</b>	<b>(0.52)</b>	<b>7.47</b>	<b>(0.01)</b>	<b>7.57</b>	<b>1.59</b>
7	<b>Profit / (loss) for the period (5-6)</b>	<b>12.90</b>	<b>(12.88)</b>	<b>22.11</b>	<b>0.02</b>	<b>22.41</b>	<b>7.70</b>
8	<b>Other comprehensive income / (loss) (net of tax)</b>						
	Items that will not be reclassified subsequently to profit or loss :						
	Re-measurement of defined benefit plans	0.26	0.13	0.33	0.39	(0.30)	0.13
	Net (loss) or gain on FVTOCI assets	(12.55)	-	(0.61)	(12.55)	(0.61)	(5.99)
	<b>Total other comprehensive income/ (loss)</b>	<b>(12.29)</b>	<b>0.13</b>	<b>(0.28)</b>	<b>(12.16)</b>	<b>(0.91)</b>	<b>(5.86)</b>
9	<b>Total comprehensive income / (loss) (after tax) (7+8)</b>	<b>0.61</b>	<b>(12.75)</b>	<b>21.83</b>	<b>(12.14)</b>	<b>21.50</b>	<b>1.84</b>
10	Paid-up equity share capital (face value of ₹ 10 each)	53.08	53.07	58.07	53.08	58.07	53.07
11	Other equity	-	-	-	-	-	366.65
12	<b>Earnings per share of ₹ 10 each:</b> (not annualised except for the year ended March)						
	a) Basic	2.43	(2.43)	3.81	-	3.86	1.38
	b) Diluted	2.42	(2.43)	3.80	-	3.85	1.37




**QUICK HEAL TECHNOLOGIES LIMITED**  
 Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014  
 CIN: L72200MH1995PLC091408

**NOTES TO THE STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023**

**Notes to financial results:**

- 1 The above financial results for the quarter and half year ended September 30, 2023 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on October 26, 2023.
- 2 Reversal of Impairment of investments  
 Included in exceptional items (₹ in crores)
- | Particulars  | Standalone                        |                              |                                   |                                   |                                   |                             |
|--|-----------------------------------|------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------|
|  | Quarter ended                     |                              | Half year ended                   |                                   |                                   | Year ended                  |
|  | September 30, 2023<br>(Unaudited) | June 30, 2023<br>(Unaudited) | September 30, 2022<br>(Unaudited) | September 30, 2023<br>(Unaudited) | September 30, 2022<br>(Unaudited) | March 31, 2023<br>(Audited) |
| Reversal of Impairment of investments in wholly owned subsidiaries | -                                 | -                            | -                                 | -                                 | -                                 | (0.10)                      |
- 3 The Board of Directors of the Company at its meeting held on July 21, 2022 and the shareholders by way of postal ballot on August 26, 2022, approved the buy back of the Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Company including promoters of the Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹ 300 per share for an aggregate amount not exceeding ₹ 150. The Company completed the Buy Back Process on October 28, 2022 and has complied with all the requisite formalities with SEBI and ROC.
- During the year ended March 31, 2023, as per the requirement of the Companies Act, 2013, an amount of ₹ 3.31 and ₹ 176.63 (Including tax on buy back of ₹ 34.94) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹ 5.00 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹ 5.00. Further, transaction cost of buy back of shares of ₹ 1.85 has been reduced from retained earnings.
- 4 The following changes have taken place in Key Managerial Personnel of the Company :  
 Mr. Srinivasa Rao Anasingaraju resigned as Company Secretary w.e.f. July 17, 2023.  
 Mr. Sarang Hari Deshpande appointed as Company Secretary w.e.f. October 26, 2023
- 5 Considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment has recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the entries carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at September 30, 2023.
- 6 The Company is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 7 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune  
 Date: October 26, 2023



For and on behalf of the Board of Directors

*(Signature)*

**Kailash Katkar**  
 Managing Director  
 DIN No: 00397191

**QUICK HEAL TECHNOLOGIES LIMITED**

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

**STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023**

₹ in crores

	As at September 30, 2023 (Unaudited)	As at March 31, 2023 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	92.69	97.57
(b) Intangible assets	1.92	2.77
(c) Intangible assets under development	0.15	0.15
(d) Investment property	27.62	24.12
(e) Investments in subsidiaries	0.81	0.81
(f) Financial assets		
(i) Investments	8.35	21.49
(ii) Other financial assets	0.82	0.76
(g) Income tax assets (net)	29.04	22.33
(h) Other non-current assets	0.70	0.65
	<b>162.10</b>	<b>170.65</b>
<b>Current assets</b>		
(a) Inventories	4.33	4.50
(b) Financial assets		
(i) Investments	163.58	176.20
(ii) Trade receivables	107.95	122.77
(iii) Cash and cash equivalents	11.46	10.29
(iv) Bank balances other than (iii) above	0.28	0.27
(v) Other financial assets	1.90	1.48
(c) Other current assets	9.89	6.73
	<b>299.39</b>	<b>322.24</b>
<b>Total assets</b>	<b>461.49</b>	<b>492.89</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
(a) Equity share capital	53.08	53.07
(b) Share application money pending allotment	0.11	-
(c) Other equity	342.81	366.65
<b>Total equity</b>	<b>396.00</b>	<b>419.72</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Net employee defined benefit liabilities	-	0.60
(b) Other non-current liabilities	1.03	0.52
(c) Deferred tax liabilities (net)	0.35	0.53
	<b>1.38</b>	<b>1.65</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	2.51	1.94
(b) Total outstanding dues creditors other than micro enterprises and enterprises	38.16	46.74
(ii) Other financial liabilities	8.44	12.73
(b) Other current liabilities	14.04	9.54
(c) Net employee defined benefit liabilities	0.96	0.57
	<b>64.11</b>	<b>71.52</b>
<b>Total liabilities</b>	<b>65.49</b>	<b>73.17</b>
<b>Total equity and liabilities</b>	<b>461.49</b>	<b>492.89</b>



<b>Quick Heal Technologies Limited</b>		
Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014		
CIN: L72200MH1995PLC091408		
STANDALONE STATEMENT OF UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2023		
₹ in crores		
	September 30, 2023	March 31, 2023
	Unaudited	Audited
<b>A. Cash flow from operating activities</b>		
Profit before tax	0.01	9.29
Adjustment to reconcile profit before tax to net cash flows:		
Exceptional items	-	(0.10)
Liability Written back	-	(1.88)
Net (gain) / loss foreign exchange differences	0.08	(0.15)
Employee share based payments expense	1.42	2.85
Depreciation and amortization expense	6.18	15.99
Interest income	0.04	(1.78)
Provision for doubtful debts and advances	4.64	5.14
Property, plant and equipment written off	0.03	-
(Profit) / loss on sale of property, plant and equipment	(0.28)	(3.95)
Income from Investment Property	(1.87)	(3.58)
Net gain on sale of investment	(0.78)	(3.20)
Net (gain) on FVTPL current investment	(5.21)	(6.88)
<b>Operating profit before working capital changes</b>	<b>4.26</b>	<b>11.75</b>
Movements in working capital:		
(Increase)/decrease in trade receivables	10.10	45.17
(Increase)/decrease in inventories	0.17	0.29
(Increase)/decrease in other financial assets	0.07	(0.86)
(Increase)/decrease in other assets	(3.21)	(3.41)
Increase/(decrease) in net employee defined benefit liabilities	0.31	0.07
Increase/(decrease) in trade payables	(8.01)	(1.51)
Increase/(decrease) in other financial liabilities	(3.06)	(2.83)
Increase/(decrease) in other current and non-current liabilities	5.01	(9.75)
<b>Cash generated from operations</b>	<b>5.64</b>	<b>38.92</b>
Direct taxes paid (net of refunds)	(7.02)	(7.93)
<b>Net cash flow from operating activities (A)</b>	<b>(1.38)</b>	<b>30.99</b>
<b>B. Cash flow from investing activities</b>		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(5.71)	(4.10)
Proceeds from sale of property, plant and equipment	0.78	5.20
Repatriation of funds / (Investments in subsidiaries)	-	2.27
Purchase of current investments	(146.84)	(400.60)
Sale of current investments	166.04	524.54
Income from Investment Property	1.87	3.58
(Increase)/decrease in bank deposits other than cash and cash equivalents	(0.01)	54.75
Interest received	(0.59)	1.86
<b>Net cash (used in) investing activities (B)</b>	<b>15.54</b>	<b>187.50</b>
<b>C. Cash flow from financing activities</b>		
Dividend paid on equity shares	(13.26)	(26.10)
Tax on Buyback	-	(34.94)
Buyback Expenses	-	(1.85)
Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP by employees	0.27	0.72
Payout for buyback of shares	-	(150.00)
<b>Net cash flow (used in) financing activities (C)</b>	<b>(12.99)</b>	<b>(212.17)</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>1.17</b>	<b>6.32</b>
Cash and cash equivalents at the beginning of the year	10.29	3.97
<b>Cash and cash equivalents at the end of the period</b>	<b>11.46</b>	<b>10.29</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	-	0.02
Balances with banks		
On current account	9.74	8.18
On EEFC account	1.72	2.09
<b>Total cash and cash equivalents</b>	<b>11.46</b>	<b>10.29</b>

